YK-11: The Only SARM That Blocks Myostatin (Complete Guide)

Origin and Discovery

YK-11 was first described by Yuichiro Kanno at Toho University in Japan in 2011. The original publication (Kanno et al., 2011, Biological and Pharmaceutical Bulletin) characterized YK-11 as a partial agonist of the androgen receptor that also induced myogenic differentiation in C2C12 cells (a mouse muscle cell line).

The key finding: YK-11-treated cells showed significantly increased expression of follistatin — the natural myostatin inhibitor — at the mRNA level. This was not observed with DHT (dihydrotestosterone) or other androgens at equivalent doses, suggesting that YK-11's follistatin induction is independent of standard androgen receptor signaling.

A follow-up study (Kanno et al., 2013) confirmed that YK-11 activated the PKB/Akt pathway and increased bone mineral density markers (osteocalcin and Runx2) in osteocytes, suggesting bone-building properties alongside its muscle effects.

What the Research Shows — and What It Doesn't

It is critical to note: all published YK-11 research is in vitro (cell cultures). There are no published animal studies and no human clinical trials. Every claim about in-vivo effects is extrapolated from cell data or derived from anecdotal user reports. This is unusual — most SARMs at least have rat studies. YK-11 went directly from bench to grey market without passing through standard pharmacological development.

This means dosing, safety, and efficacy in humans are entirely empirical. What follows is synthesized from the available mechanistic data, structural analysis, and the substantial body of user experience that has accumulated since YK-11 entered the research chemical market.

---

Mechanism of Action: The Dual Pathway

Pathway 1: Partial Androgen Receptor Agonism

YK-11 binds the androgen receptor as a partial agonist. "Partial" means it activates the receptor at a fraction of the intensity that full agonists (testosterone, DHT) do. In practice, this translates to:

• Anabolic signaling in muscle tissue (muscle protein synthesis, nitrogen retention)
• Reduced androgenic signaling in non-target tissues (prostate, skin, scalp — though not zero)
• HPTA suppression (the hypothalamus detects androgen receptor activation and reduces gonadotropin output)

The partial agonism is what technically qualifies it as a "SARM" — selective activation in some tissues but not others. However, YK-11's selectivity ratio has never been formally quantified in vivo.

Pathway 2: Follistatin Induction → Myostatin Inhibition

This is what makes YK-11 unique. Through a mechanism that appears independent of its androgen receptor activity (potentially involving the Wnt signaling pathway), YK-11 upregulates follistatin gene expression in muscle cells. Elevated follistatin binds and neutralizes circulating myostatin, removing the growth-limiting signal.

The practical implication: YK-11 attacks muscle growth limitation from two directions simultaneously — adding anabolic signal while removing anti-anabolic signal. No other commercially available SARM does both.

Why This Matters for Results

Standard SARMs like LGD-4033 or RAD-140 press the accelerator (more anabolic signal). But they do not release the brakes (myostatin still limits growth). Full-dose testosterone does the same — massive anabolic drive pushing against a growth ceiling that myostatin enforces.

YK-11 both presses the accelerator AND releases a brake. This explains anecdotal reports of YK-11 producing disproportionate mass gains relative to its apparently modest androgen receptor affinity.

---

The Steroidal Structure Problem

Look at YK-11's molecular structure and you will see a 19-nor steroid backbone with modifications at the 17-alpha position (a methyl group) and the D-ring (a unique spirocyclic structure). This is not a non-steroidal SARM like ostarine or RAD-140.

17-Alpha Methylation: The Liver Concern

The methyl group at the 17-alpha position is the same modification found in oral anabolic steroids like Dianabol, Winstrol, and Anavar. This modification exists for one reason: to prevent first-pass hepatic metabolism so the compound survives oral administration.

The trade-off is hepatotoxicity. Methylated compounds stress the liver by:

1. Resisting conjugation and clearance pathways
2. Causing cholestasis (impaired bile flow)
3. Elevating liver enzymes (ALT, AST, GGT)
4. Altering lipid metabolism (HDL suppression, LDL elevation)

YK-11 carries this same liability. Unlike LGD-4033 or RAD-140 (which are non-methylated and liver-friendly at standard doses), YK-11 requires liver support and has a maximum recommended cycle duration comparable to oral steroids, not other SARMs.

---

Dosing Protocol

Standard Protocol

Dose Breakdown

• 5mg/day: Conservative. Suitable for first-time users, those stacking with other compounds, or those prioritizing safety. Still produces noticeable strength and mass increases.
• 10mg/day: Standard. The most commonly reported dose in user logs. Significant muscle fullness, strength increase, and body composition improvement. Liver stress becomes more relevant.
• 15mg/day: Aggressive. Some experienced users push to this level. Hepatic strain increases substantially. Diminishing returns on muscle gain relative to additional liver stress. Not recommended for most.

Cycle Length Rationale

The 6-8 week limit is driven by hepatotoxicity, not by receptor desensitization or diminishing anabolic returns. Liver enzymes typically begin rising at week 3-4 and can reach concerning levels by week 8-10 at standard doses. Users should obtain baseline liver panels before starting and recheck at week 4.

Split Dosing

Given the estimated 6-10 hour half-life, single daily dosing creates significant peak-trough variation. Splitting into two equal doses (morning and early afternoon) maintains more stable blood levels. For the 10mg/day protocol: 5mg upon waking, 5mg 8 hours later.

---

Required Support Supplements

Unlike most SARMs where support supplements are optional, YK-11 demands them:

Liver Protection (Non-Negotiable)

• NAC (N-Acetyl Cysteine): 600-1200mg/day. Glutathione precursor that supports phase II liver detoxification.
• TUDCA (Tauroursodeoxycholic acid): 250-500mg/day. Bile acid that directly protects hepatocytes and prevents cholestasis.
• Milk Thistle (Silymarin): 600-1200mg/day. Supportive but weaker than NAC/TUDCA.

[Internal Link: /nac/]

Lipid Support

• Fish oil: 3-5g/day (high EPA/DHA) for HDL support
• Citrus bergamot: 500-1000mg/day for cholesterol management
• Red yeast rice: 1200mg/day if LDL elevation is significant

Joint Support

Rapid strength gains can outpace connective tissue adaptation:

• Collagen peptides: 10-15g/day
• Vitamin C: 500mg/day (required for collagen synthesis)

---

What to Expect: Timeline

Week 1-2

• Increased muscle fullness (glycogen retention, not yet true hypertrophy)
• Noticeable strength increase (5-10% on compound lifts is typical)
• Enhanced mind-muscle connection
• Possible mild aggression/assertiveness increase

Week 3-4

• Visible body composition changes (fuller muscles, reduced softness)
• Strength continues climbing (10-20% over baseline)
• Weight gain of 4-8 lbs (mix of muscle, glycogen, water)
• Recovery between sessions noticeably improved

Week 5-8

• Peak anabolic effect
• Total lean mass gain of 6-12 lbs possible (some water/glycogen will be lost post-cycle)
• Strength plateau as androgen receptor saturation occurs
• Liver enzymes likely elevated (monitor)

Post-Cycle

• Some mass lost (glycogen, water) in first 2 weeks
• Keepable gains with proper PCT: typically 60-75% of on-cycle weight gain
• Testosterone recovery takes 4-8 weeks depending on cycle length and individual response

---

Side Effects

Confirmed/Likely

• Testosterone suppression: YK-11 is suppressive. The degree varies by dose and duration, but most users at 10mg/day for 8 weeks report significant suppression requiring PCT. Blood work confirms LH and FSH reduction.
• Liver stress: Elevated ALT, AST. Typically 2-4x upper normal range at standard doses. Returns to baseline 4-6 weeks post-cycle with liver support.
• HDL suppression / LDL elevation: Lipid profiles shift toward atherogenic pattern during cycle. Reversible post-cycle.
• Hair shedding: Users with male pattern baldness predisposition report accelerated shedding. YK-11's partial androgenic activity can trigger miniaturization in susceptible follicles.
• Aggression/irritability: Some users report mood changes consistent with elevated androgen signaling.

Possible

• Joint dryness: Some reports of reduced synovial fluid production (similar to Winstrol-like drying effects). May relate to lipid changes rather than direct joint action.
• Acne: Androgenic side effect in susceptible individuals. Less common than with full androgens but reported.
• Lethargy (late cycle): As suppression accumulates, some users report fatigue by weeks 6-8.

Compared to Other SARMs

---

PCT Protocol After YK-11

Due to its suppressive nature, PCT is strongly recommended after any YK-11 cycle exceeding 4 weeks:

Standard PCT

• Enclomiphene or Clomiphene: 25-50mg/day for 4 weeks
• OR Nolvadex (Tamoxifen): 20mg/day for 4 weeks
• Continue NAC and TUDCA through PCT for liver recovery

Blood Work Schedule

1. Baseline (before cycle): Total testosterone, free testosterone, LH, FSH, liver panel, lipid panel
2. Mid-cycle (week 4): Liver panel, lipids
3. End of cycle: Full hormone panel + liver + lipids
4. Post-PCT (4 weeks after PCT ends): Full hormone panel to confirm recovery

[Internal Link: /enclomiphene/]

---

YK-11 vs. Follistatin 344: Detailed Comparison

Both target myostatin, but through entirely different mechanisms. Understanding the differences determines which is appropriate for your protocol:

Mechanism Difference

YK-11: Enters the cell → activates androgen receptor → upregulates follistatin gene expression → follistatin is produced by your cells → binds myostatin

Follistatin 344: Inject follistatin directly → immediately binds myostatin in circulation

YK-11's pathway is indirect and depends on your cells' capacity to produce follistatin. Follistatin 344 bypasses this entirely.

Practical Differences

Stacking Both

Advanced users occasionally stack YK-11 + Follistatin 344 for maximum myostatin suppression from both angles. This is an aggressive approach that addresses myostatin through both endogenous production (YK-11 → more follistatin) and exogenous direct binding (injected follistatin). The cost is substantial and the incremental benefit over either alone is uncertain.

---

Stacking YK-11 with Other Compounds

YK-11 + MK-677

The most popular YK-11 stack. MK-677 provides GH/IGF-1 elevation without suppression, while YK-11 provides androgen receptor activation plus myostatin inhibition. The combination attacks muscle growth from three pathways simultaneously. MK-677's appetite stimulation also supports the caloric surplus needed to capitalize on YK-11's anabolic potential.

[Internal Link: /mk-677/]

YK-11 + RAD-140

Dual SARM stack for maximum mass. RAD-140 provides stronger direct androgen receptor agonism while YK-11 adds the follistatin/myostatin mechanism. Highly suppressive — robust PCT mandatory. Liver support critical (YK-11 is methylated; RAD-140 is not, so liver burden is primarily from YK-11).

[Internal Link: /rad-140/]

YK-11 + Testosterone Base

For users already on TRT or blast doses, adding YK-11 provides the myostatin inhibition angle that testosterone alone cannot. The partial agonism of YK-11 is less relevant when exogenous testosterone is saturating the androgen receptor — the value is purely in the follistatin induction.

What NOT to Stack With

• Other methylated oral compounds (Dianabol, Superdrol, Winstrol): Compounding liver stress is dangerous
• Hepatotoxic SARMs at high doses (S-23 at aggressive doses): Same liver concern
• Alcohol: Should be eliminated or minimized during any YK-11 cycle

---

Canadian Context

YK-11 is not approved for human use in Canada and is sold strictly as a research chemical. It is not a controlled substance and can be legally purchased for research purposes. Import from international suppliers is generally unrestricted for personal research quantities.

Canadian peptide and research chemical suppliers stock YK-11 in both liquid suspension and powder form. Capsules are also available from some vendors, though purity verification is more difficult with pre-encapsulated products. Third-party testing (HPLC purity certificates) should be demanded from any supplier.

[Internal Link: /sarms-canada/]

---

Frequently Asked Questions

Is YK-11 actually a SARM?

Technically debatable. Its steroidal structure, 17-alpha methylation, and mechanism of action differ significantly from non-steroidal SARMs like ostarine or LGD-4033. It is categorized with SARMs because it demonstrates selective androgen receptor modulation (partial agonism), but structurally and pharmacologically it is closer to an oral anabolic steroid with a unique secondary mechanism.

Can I run YK-11 without PCT?

Not recommended at any dose above 5mg/day for more than 4 weeks. Blood work consistently shows LH/FSH suppression and total testosterone decline in users running standard protocols. Without PCT, testosterone recovery may take 2-4 months — during which muscle loss and low-T symptoms (fatigue, libido loss, mood depression) are likely.

How does YK-11 compare to RAD-140 for mass?

YK-11 typically produces more raw mass gain than RAD-140 at equivalent cycle lengths, primarily due to the additional follistatin/myostatin mechanism. However, RAD-140 is significantly safer (non-methylated, less suppressive, no liver toxicity) and produces very good results on its own. RAD-140 is the better choice for most users; YK-11 is for those who accept higher risk for additional gains.

Will YK-11 cause hair loss?

If you carry the genetic predisposition for male pattern baldness (sensitivity to androgenic signaling in scalp follicles), YK-11 can accelerate hair loss. The risk is lower than with full androgens like testosterone or DHT derivatives, but higher than with truly selective SARMs like ostarine. Users concerned about hair should consider RU-58841 topically or avoid YK-11 entirely.

What is the minimum effective dose?

Anecdotal reports suggest noticeable effects begin at 5mg/day. Some users report results at 2.5mg/day, though this is below the dose used in cell studies when scaled for body weight. Starting at 5mg/day for the first cycle allows assessment of individual response and side effect profile before considering dose escalation.

---

Conclusion

YK-11 occupies a unique position in the performance enhancement landscape. It is the only commercially available compound that combines androgen receptor modulation with myostatin inhibition through follistatin induction. This dual mechanism makes it arguably the most potent mass-building option in the SARM category — but its steroidal structure and 17-alpha methylation mean it carries risks that true SARMs do not.

The intelligent approach: use YK-11 when you specifically want the myostatin inhibition mechanism and are willing to manage the liver and suppression trade-offs. Support it with NAC, TUDCA, and proper PCT. Monitor blood work. Respect the 6-8 week maximum. And recognize that this is not a beginner compound — it demands the same respect as mild oral steroids because, structurally and pharmacologically, that is what it resembles.

For those who approach it with appropriate caution and proper support, YK-11 delivers results that no other SARM can match.

[Internal Link: /sarms-stacks/]

---

Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before beginning any SARM or research compound protocol.